Thymosin Alpha-1 vs KPV

Immune

Immune

Research Only

Research Only

Tα1 acts primarily on dendritic cells and T-cells via Toll-like receptor signaling — TLR9-MyD88-IRF7 driving type I interferon, and TLR2-MyD88-NF-κB driving IL-12, TNF-α, and IL-6. It promotes dendritic cell maturation, T-cell differentiation and thymic output, enhances NK cell cytotoxicity, upregulates MHC class I expression, and induces indoleamine 2,3-dioxygenase (IDO) to balance inflammation with tolerance. Unlike broad cytokine stimulators, Tα1 is a context-dependent immunomodulator that can enhance deficient responses and restrain overactive ones.

KPV enters cells (in part via the di/tripeptide transporter PepT1 in intestinal epithelium and immune cells) and acts intracellularly to inhibit NF-kB activation, reducing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β). Unlike full-length alpha-MSH, KPV does not meaningfully activate MC1R and does not cause skin pigmentation, differentiating it from melanocortin agonists such as MT-I and MT-II.

1.6 mg

200–500 mcg (SubQ); 500 mcg–1 mg (oral)

SubQ

Oral, SubQ, or Topical

2x per week

1–2 times daily

Standard Zadaxin label dose is 1.6 mg SubQ twice weekly (typical 6-12 month courses in HBV/HCV). Grey-market research protocols often use 1.6–3.2 mg SubQ 2x/week in 4–8 week cycles. Half-life ~2 hours after SubQ administration.

All dosing is grey-market and not clinically validated. Oral protocols target gut inflammation; SubQ used for systemic effects; topical for localized skin conditions.